The meninges: new therapeutic targets for multiple sclerosis.

The central nervous system (CNS) largely comprises nonregenerating cells, including neurons and myelin-producing oligodendrocytes, which are particularly vulnerable to immune cell-mediated damage. To protect the CNS, mechanisms exist that normally restrict the transit of peripheral immune cells into the brain and spinal cord, conferring an "immune-specialized" status. Thus, there has been a long-standing debate as to how these restrictions are overcome in several inflammatory diseases of the CNS, including multiple sclerosis (MS). In this review, we highlight the role of the meninges, tissues that surround and protect the CNS and enclose the cerebral spinal fluid, in promoting chronic inflammation that leads to neuronal damage. Although the meninges have traditionally been considered structures that provide physical protection for the brain and spinal cord, new data have established these tissues as sites of active immunity. It has been hypothesized that the meninges are important players in normal immunosurveillance of the CNS but also serve as initial sites of anti-myelin immune responses. The resulting robust meningeal inflammation elicits loss of localized blood-brain barrier (BBB) integrity and facilitates a large-scale influx of immune cells into the CNS parenchyma. We propose that targeting the cells and molecules mediating these inflammatory responses within the meninges offers promising therapies for MS that are free from the constraints imposed by the BBB. Importantly, such therapies may avoid the systemic immunosuppression often associated with the existing treatments.

[1]  N. Thomson,et al.  IL-33 induces innate lymphoid cell–mediated airway inflammation by activating mammalian target of rapamycin , 2012, The Journal of allergy and clinical immunology.

[2]  R. Tubbs,et al.  The pia mater: a comprehensive review of literature , 2013, Child's Nervous System.

[3]  A. Baxter,et al.  The origin and application of experimental autoimmune encephalomyelitis , 2007, Nature Reviews Immunology.

[4]  M. Forrest,et al.  Sphingosine-1-Phosphate Receptor Agonism Impairs the Efficiency of the Local Immune Response by Altering Trafficking of Naive and Antigen-Activated CD4+ T Cells , 2003, The Journal of Immunology.

[5]  Robert Zivadinov,et al.  Gray matter atrophy and disability progression in patients with early relapsing–remitting multiple sclerosis A 5-year longitudinal study , 2009, Journal of the Neurological Sciences.

[6]  S. Maier,et al.  A novel immune-to-CNS communication pathway: Cells of the meninges surrounding the spinal cord CSF space produce proinflammatory cytokines in response to an inflammatory stimulus , 2007, Brain, Behavior, and Immunity.

[7]  S. Rivest,et al.  Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood–brain barrier , 1999, Neuroscience.

[8]  J. Geurts,et al.  Meningeal Inflammation is not Associated With Cortical Demyelination in Chronic Multiple Sclerosis , 2009, Journal of neuropathology and experimental neurology.

[9]  Wojciech Pawlina,et al.  Comprar Histology: A Text and Atlas, 7ª Ed. With Correlated Cell And Molecular Biology | Michael H Ross | 9781469889313 | Lippincott Williams & Wilkins , 2015 .

[10]  Jonathan D Rodgers,et al.  Characterizing cognitive function during relapse in multiple sclerosis , 2014, Multiple sclerosis.

[11]  R. Voskuhl,et al.  Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. , 1997, Journal of immunology.

[12]  R. Kuzniecky,et al.  An implantable triple-function device for local drug delivery, cerebrospinal fluid removal and EEG recording in the cranial subdural/subarachnoid space of primates , 2012, Journal of Neuroscience Methods.

[13]  D. Metcalfe,et al.  Induction and enhancement of Fc(epsilon)RI-dependent mast cell degranulation following coculture with activated T cells: dependency on ICAM-1- and leukocyte function-associated antigen (LFA)-1-mediated heterotypic aggregation. , 1998, Journal of immunology.

[14]  S. Amor,et al.  Abundant extracellular myelin in the meninges of patients with multiple sclerosis , 2009, Neuropathology and applied neurobiology.

[15]  Alberto Romagnolo,et al.  Involvement of the choroid plexus in multiple sclerosis autoimmune inflammation: A neuropathological study , 2008, Journal of Neuroimmunology.

[16]  Lawrence Steinman,et al.  How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis , 2006, Annals of neurology.

[17]  J. Parisi,et al.  Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination. , 2011, Archives of neurology.

[18]  B. Becher,et al.  Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis , 2005, Nature Medicine.

[19]  H. Weiner,et al.  Role of Mast Cells in Peripheral Nervous System Demyelination , 1988, Annals of the New York Academy of Sciences.

[20]  T. Pufe,et al.  Expression and regulation of antimicrobial peptide rCRAMP after bacterial infection in primary rat meningeal cells , 2009, Journal of Neuroimmunology.

[21]  B. Bielekova,et al.  Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis , 2012, Science Translational Medicine.

[22]  D. Linthicum,et al.  Mast cell‐derived histamine and tumour necrosis factor: Differences between SJL/J and BALB/c inbred strains of mice , 1996, Immunology and cell biology.

[23]  W. Ouyang,et al.  A role for Th17 cells in the regulation of tertiary lymphoid follicles , 2012, European journal of immunology.

[24]  M. Simons,et al.  Chronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies , 2010, Current neuropharmacology.

[25]  D. Arnold,et al.  A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis , 2014, Journal of Neurology.

[26]  C. Gasperini,et al.  Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies , 2013, Expert opinion on investigational drugs.

[27]  H. Wekerle,et al.  Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions , 2009, Nature.

[28]  D. Wakefield,et al.  Mast cell activation and migration to lymph nodes during induction of an immune response in mice. , 1998, The Journal of clinical investigation.

[29]  W. Reith,et al.  TGFbeta receptor II gene deletion in leucocytes prevents cerebral vasculitis in bacterial meningitis. , 2006, Brain : a journal of neurology.

[30]  H. Hartung,et al.  Animal models of multiple sclerosis—Potentials and limitations , 2010, Progress in Neurobiology.

[31]  R. Ransohoff Immunology: In the beginning , 2009, Nature.

[32]  R. Reynolds,et al.  Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. , 2011, Brain : a journal of neurology.

[33]  Lisbeth Illum,et al.  Nanoparticles for direct nose-to-brain delivery of drugs. , 2009, International journal of pharmaceutics.

[34]  A. Vandenbark,et al.  Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. , 1999, Journal of immunology.

[35]  C. Polman,et al.  Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS , 2004, Neurology.

[36]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[37]  A. Reder,et al.  The mast cells of the multiple sclerosis brain , 1996, Journal of Neuroimmunology.

[38]  B. Melchior,et al.  CNS immune privilege: hiding in plain sight , 2006, Immunological reviews.

[39]  V. ter meulen,et al.  Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Voskuhl,et al.  Sex Hormones in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis , 2001, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[41]  G. Anderson,et al.  OX40 and CD30 signals in CD4+ T‐cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4+ T‐cell memory but not effector function , 2011, Immunological reviews.

[42]  R. Reynolds,et al.  A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis , 2010, Annals of neurology.

[43]  R. Ransohoff,et al.  Localizing central nervous system immune surveillance: Meningeal antigen‐presenting cells activate T cells during experimental autoimmune encephalomyelitis , 2009, Annals of neurology.

[44]  J. Parisi,et al.  A case of multiple sclerosis presenting with inflammatory cortical demyelination , 2011, Neurology.

[45]  J. Tigges,et al.  Subarachnoid space of the CNS, nasal mucosa, and lymphatic system. , 1979, Archives of otolaryngology.

[46]  Melissa A Brown,et al.  The master switch: the role of mast cells in autoimmunity and tolerance. , 2008, Annual review of immunology.

[47]  L. Tuomisto,et al.  Histamine and histamine-N-methyltransferase in the CSF of patients with multiple sclerosis , 1983, Agents and Actions.

[48]  M. Krampera,et al.  Meninges: from protective membrane to stem cell niche. , 2012, American journal of stem cells.

[49]  F. Safavi,et al.  The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.

[50]  R. Ransohoff,et al.  Human cerebrospinal fluid central memory CD4+ T cells: Evidence for trafficking through choroid plexus and meninges via P-selectin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Dongmei Sun,et al.  Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[52]  P. Ascierto,et al.  Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination , 2013, Clinical Cancer Research.

[53]  M. Khorramizadeh,et al.  Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants. , 2014, Iranian journal of allergy, asthma, and immunology.

[54]  S. Hauser,et al.  Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients , 1995, Annals of neurology.

[55]  C. Weyand,et al.  Ectopic Germinal Center Formation in Rheumatoid Synovitis , 2003, Annals of the New York Academy of Sciences.

[56]  M. H. Ross,et al.  Histology: A Text and Atlas , 1985 .

[57]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[58]  M. Bynoe,et al.  A2A Adenosine Receptor Signaling in Lymphocytes and the Central Nervous System Regulates Inflammation during Experimental Autoimmune Encephalomyelitis , 2012, The Journal of Immunology.

[59]  P. O'Connor Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. , 2007, Expert opinion on biological therapy.

[60]  H. Weiner,et al.  The role of mast cells in demyelination. 1. Myelin proteins are degraded by mast cell proteases and myelin basic protein and P2 can stimulate mast cell degranulation , 1988, Brain Research.

[61]  W. Banks,et al.  Intranasal Administration as a Route for Drug Delivery to the Brain: Evidence for a Unique Pathway for Albumin , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[62]  W. Aulitzky,et al.  Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™) , 2008, Therapeutics and clinical risk management.

[63]  C. Gutekunst,et al.  Mast Cells Are Essential for Early Onset and Severe Disease in a Murine Model of Multiple Sclerosis , 2000, The Journal of experimental medicine.

[64]  Richard Reynolds,et al.  Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. , 2013, Brain : a journal of neurology.

[65]  S. Hauser,et al.  The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration , 2006, Neuron.

[66]  P. O'Connor Natalizumab and the role of α4-integrin antagonism in the treatment of multiple sclerosis , 2007 .

[67]  Melissa A Brown,et al.  Mast Cells , 2008, Annals of the New York Academy of Sciences.

[68]  B. Engelhardt,et al.  C-C chemokine receptor 6–regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE , 2009, Nature Immunology.

[69]  A. McKenzie,et al.  Innate lymphoid cells — how did we miss them? , 2013, Nature Reviews Immunology.

[70]  Simon C. Potter,et al.  Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis , 2011, Nature.

[71]  D. Hinrichs,et al.  Mast cell proteases liberate stable encephalitogenic fragments from intact myelin. , 1991, Cellular immunology.

[72]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[73]  R. Reynolds,et al.  Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. , 2012, Brain : a journal of neurology.

[74]  J. Quevedo,et al.  Inhibition of indoleamine 2,3-dioxygenase prevented cognitive impairment in adult Wistar rats subjected to pneumococcal meningitis. , 2013, Translational research : the journal of laboratory and clinical medicine.

[75]  Hartwig Wolburg,et al.  Choroid plexus: biology and pathology , 2009, Acta Neuropathologica.

[76]  M. E. Walker,et al.  Cutting Edge: Mast Cells Regulate Disease Severity in a Relapsing–Remitting Model of Multiple Sclerosis , 2011, The Journal of Immunology.

[77]  D. J. Neumann Ueber das Vorkommen der sogenannten „Mastzellen” bei pathologischen Veränderungen des Gehirns , 1890, Archiv für pathologische Anatomie und Physiologie und für klinische Medicin.

[78]  I. McGregor,et al.  The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis , 2014, Brain, Behavior, and Immunity.

[79]  M. Oukka,et al.  IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism , 2013, Mucosal Immunology.

[80]  R. Reynolds,et al.  Meningeal T cells associate with diffuse axonal loss in multiple sclerosis spinal cords , 2010, Annals of neurology.

[81]  Sumana Chakravarty,et al.  Toll-Like Receptor 4 on Nonhematopoietic Cells Sustains CNS Inflammation during Endotoxemia, Independent of Systemic Cytokines , 2005, The Journal of Neuroscience.

[82]  R. Friede,et al.  The origin of subdural neomembranes. I. Fine structure of the dura-arachnoid interface in man. , 1978, The American journal of pathology.

[83]  E. Fabbretti,et al.  Mast cell activation by myelin through scavenger receptor , 2008, Journal of Neuroimmunology.

[84]  P. Robbins,et al.  Induction of pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific serum factors , 2011, Journal of Neuroimmunology.

[85]  P. Nichelli,et al.  Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM , 2011, Multiple sclerosis.

[86]  J. Geurts,et al.  Gray matter imaging in multiple sclerosis: what have we learned? , 2011, BMC neurology.

[87]  Meena Subramanyam,et al.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy. , 2012, The New England journal of medicine.

[88]  C. V. Jensen,et al.  Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis , 2001, European journal of neurology.

[89]  H. Hartung,et al.  Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis , 2013, Neurology.

[90]  C. Whitacre Sex differences in autoimmune disease , 2001, Nature Immunology.

[91]  K. Peterson,et al.  TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. , 2011, The American journal of pathology.

[92]  R. Ransohoff,et al.  Animal models of multiple sclerosis: the good, the bad and the bottom line , 2012, Nature Neuroscience.

[93]  D. Hinrichs,et al.  The role of mast cells in the elicitation of experimental allergic encephalomyelitis. , 1989, Journal of immunology.

[94]  Ondrej Dolezal,et al.  Clinical correlates of grey matter pathology in multiple sclerosis , 2012, BMC Neurology.

[95]  J. Foley,et al.  Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action , 2013, Biologics : targets & therapy.

[96]  R. Dantzer,et al.  Interleukin-10 in the brain. , 2001, Critical reviews in immunology.

[97]  P. Sawchenko,et al.  Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis , 2007, The Journal of comparative neurology.

[98]  M. Hessner,et al.  Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE. , 2013, Journal of autoimmunity.

[99]  Rohit Bakshi,et al.  Gray matter involvement in multiple sclerosis , 2007, Neurology.

[100]  M. Tsai,et al.  Mast Cells Enhance T Cell Activation: Importance of Mast Cell Costimulatory Molecules and Secreted TNF1 , 2006, The Journal of Immunology.

[101]  Eric Vivier,et al.  Innate lymphoid cells — a proposal for uniform nomenclature , 2013, Nature Reviews Immunology.

[102]  R. Weller Microscopic morphology and histology of the human meninges. , 2005, Morphologie : bulletin de l'Association des anatomistes.

[103]  Yukihiko Kitamura,et al.  Decrease of mast cells in w/wv mice and their increase by bone marrow transplantation. , 1978 .

[104]  W. Ong,et al.  Nose-to-brain drug delivery by nanoparticles in the treatment of neurological disorders. , 2014, Current medicinal chemistry.

[105]  S. Gold,et al.  Estrogen and testosterone therapies in multiple sclerosis. , 2009, Progress in brain research.

[106]  H. Ovadia,et al.  Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis , 2013, Journal of Neuroimmunology.

[107]  B. Serafini,et al.  Detection of Ectopic B‐cell Follicles with Germinal Centers in the Meninges of Patients with Secondary Progressive Multiple Sclerosis , 2004, Brain pathology.

[108]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[109]  R. Reynolds,et al.  Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. , 2010, Brain : a journal of neurology.

[110]  O. Kirmi,et al.  Anatomy and imaging of the normal meninges. , 2009, Seminars in ultrasound, CT, and MR.

[111]  A. Coles Alemtuzumab Therapy for Multiple Sclerosis , 2012, Neurotherapeutics.

[112]  U. Wagner,et al.  The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis. , 1998, Journal of immunology.

[113]  H. Gerber,et al.  Targeting CD30/CD30L in oncology and autoimmune and inflammatory diseases. , 2009, Advances in experimental medicine and biology.

[114]  John T. Chang,et al.  Inducible MHC Class II Expression by Mast Cells Supports Effector and Regulatory T Cell Activation 1 , 2009, The Journal of Immunology.

[115]  S. Mahurkar,et al.  Identification of Shared Genes and Pathways: A Comparative Study of Multiple Sclerosis Susceptibility, Severity and Response to Interferon Beta Treatment , 2013, PloS one.

[116]  Leah M. Alabanza,et al.  Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis , 2012, Journal of Neuroinflammation.

[117]  S. Travis,et al.  IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease , 2011, The Journal of experimental medicine.

[118]  David Artis,et al.  Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus , 2011, Nature Immunology.

[119]  P. Calabresi,et al.  Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases , 2005, Molecular Pharmacology.

[120]  A. Minagar,et al.  The Role of Alpha-4 Integrin in the Aetiology of Multiple Sclerosis , 2005, CNS drugs.

[121]  Jiwon Oh,et al.  Teriflunomide for the Treatment of Multiple Sclerosis , 2013, Seminars in Neurology.

[122]  P. Sawchenko,et al.  Type 1 interleukin‐1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL‐1–induced cellular activation , 1995, The Journal of comparative neurology.

[123]  P. Maher,et al.  Effects of dimethyl fumarate on neuroprotection and immunomodulation , 2012, Journal of Neuroinflammation.

[124]  F. Sánchez‐Madrid,et al.  Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. , 1992, Nature.

[125]  B. Solomon,et al.  Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope , 2010, Journal of Neuroimmunology.

[126]  G. I. Hatton,et al.  Anatomy of the brain neurogenic zones revisited: Fractones and the fibroblast/macrophage network , 2002, The Journal of comparative neurology.

[127]  R. Kuzniecky,et al.  Autoradiographic evidence for the transmeningeal diffusion of muscimol into the neocortex in rats , 2012, Brain Research.

[128]  Leah M. Feazel,et al.  Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity , 2013, Science.

[129]  S. Jalkanen,et al.  CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis , 2008, Proceedings of the National Academy of Sciences.

[130]  B. Weinshenker,et al.  Multiple sclerosis. , 2000, The New England journal of medicine.

[131]  M. Juan,et al.  Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. , 2001, The American journal of pathology.

[132]  M Rovaris,et al.  Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[133]  Hans Lassmann,et al.  Multiple sclerosis and Alzheimer's disease , 2008, Annals of neurology.

[134]  C. Whitacre,et al.  Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains , 2004, Journal of Neuroimmunology.

[135]  E. Fish The X-files in immunity: sex-based differences predispose immune responses , 2008, Nature Reviews Immunology.

[136]  M. Dwyer,et al.  Subcortical and Cortical Gray Matter Atrophy in a Large Sample of Patients with Clinically Isolated Syndrome and Early Relapsing-Remitting Multiple Sclerosis , 2012, American Journal of Neuroradiology.

[137]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[138]  P. Calabresi,et al.  Kv1.3 Deletion Biases T Cells toward an Immunoregulatory Phenotype and Renders Mice Resistant to Autoimmune Encephalomyelitis , 2012, The Journal of Immunology.

[139]  K. Dev,et al.  The structure and function of the S1P1 receptor. , 2013, Trends in pharmacological sciences.

[140]  J. Gauldie,et al.  IFN-γ-Induced Chemokines Synergize with Pertussis Toxin to Promote T Cell Entry to the Central Nervous System1 , 2007, The Journal of Immunology.

[141]  F. Patti,et al.  Gray Matters in Multiple Sclerosis: Cognitive Impairment and Structural MRI , 2014, Multiple sclerosis international.

[142]  A. Bar-Or,et al.  Teriflunomide and Its Mechanism of Action in Multiple Sclerosis , 2014, Drugs.

[143]  Hernández-Pando Rogelio,et al.  Pathogenesis and immune response in tuberculous meningitis. , 2014, The Malaysian journal of medical sciences : MJMS.

[144]  R. Ravid,et al.  Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system , 2002, Journal of Neuroimmunology.

[145]  M. E. Walker,et al.  Meningeal Mast Cells Affect Early T Cell Central Nervous System Infiltration and Blood-Brain Barrier Integrity through TNF: A Role for Neutrophil Recruitment? , 2010, The Journal of Immunology.

[146]  C. Lucchinetti,et al.  Meningeal and cortical grey matter pathology in multiple sclerosis , 2012, BMC Neurology.

[147]  G. Wahl,et al.  Mechanism of action for leflunomide in rheumatoid arthritis. , 1999, Clinical immunology.